Regencell Bioscience Holdings (RGC) Notes Payables (2021 - 2025)

Regencell Bioscience Holdings' (RGC) quarterly Notes Payables came in at $106.0 in Q4 2025, down 95.83% on a QoQ basis from $2539.0 in Q2 2025.

Regencell Bioscience Holdings (RGC) Notes Payables (2021 - 2025) Analysis & Trends

Regencell Bioscience Holdings (RGC) has 5 years of Notes Payables data on file, last reported at $106.0 in Q4 2025.

Quarterly Notes Payables changed N/A year-over-year to $106.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $106.0 (changed N/A YoY) and the FY2025 annual result came in at $2539.0, down 69.93% from the prior year.
Notes Payables eased to $106.0 in Q4 2025, from $2539.0 in the prior quarter.
In the past five years, Notes Payables ranged from a high of $3.2 million in Q2 2021 to a low of $106.0 in Q4 2025.
A 5-year average of $547884.7 and a median of $9506.5 in 2023 frame the typical range for Notes Payables.
Annual changes were most pronounced in 2022 — Notes Payables sank 99.52% — and 2024, when it fell 20.12%.
Tracing RGC's Notes Payables over 5 years: stood at $3.2 million in 2021, then tumbled by 99.52% to $15650.0 in 2022, then sank by 32.46% to $10570.0 in 2023, then slipped by 20.12% to $8443.0 in 2024, then plunged by 98.74% to $106.0 in 2025.
The last three Notes Payables figures came in at $106.0 (Q4 2025), $2539.0 (Q2 2025), and $8443.0 (Q2 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-
10	Regencell Bioscience Holdings	2.67 Bn	2.67 Bn	-

Download Data